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ABSTRACT
The completion of the sequencing of the human
genome and the concurrent, rapid development of
high-throughput proteomic methods have resulted
in an increasing need for automated approaches to
archive proteomic data in a repository that enables
the exchange of data among researchers and also
accurate integration with genomic data. Peptide-
Atlas (http://www.peptideatlas.org/) addresses these
needs by identifying peptides by tandem mass spec-
trometry (MS/MS), statistically validating those iden-
tifications and then mapping identified sequences to
the genomes of eukaryotic organisms. A meaningful
comparisonofdataacrossdifferentexperimentsgen-
erated by different groups using different types of
instruments is enabled by the implementation of a
uniformanalyticprocess.This uniform statisticalval-
idation ensures a consistent and high-quality set of
peptideandproteinidentifications.Therawdatafrom
many diverse proteomic experiments are made avail-
able in the associated PeptideAtlas repository in
several formats. Here we present a summary of our
processanddetailsabouttheHuman,Drosophilaand
Yeast PeptideAtlas builds.
INTRODUCTION
PeptideAtlas was initially designed to annotate eukaryotic
genomes with peptide sequences obtained from mass spectro-
metry (MS) experiments. These peptide sequences can be
collected using the procedure summarized in Figure 1. Sample
proteins are proteolytically cleaved into peptides (usually by
the enzyme trypsin although other proteases can also be used).
The resulting peptide mixture is then subjected to chromato-
graphic separation by strong cation exchange and reverse
phase capillary chromatography. The resulting peptide
pools are then analyzed by ESI-MS/MS. The database search
program SEQUEST (1) is used to assign a peptide sequence
to the MS/MS spectra. The conﬁdence of these peptide assign-
ments is then evaluated using PeptideProphet (2), which
assigns a probability P of being correct to each top-scoring
peptide sequence identiﬁcation. All the experimental data pro-
ducts, including PeptideProphet probability scores, are loaded
into SBEAMS—Proteomics, a proteomics analysis database
built as a module under the Systems Biology Experiment
Analysis Management System (SBEAMS) framework
(http://www.sbeams.org/).
The identiﬁed peptide sequences are then mapped onto their
respective genome sequence. First a modiﬁed BLAST (3)
algorithm is used (with the parameters adapted for searching
small peptides: -E 1 -W 2 -M PAM30 -G 9 -e 10 -K 50 -b 50 -F
F) to exactly match each peptide to an organism’s reference
protein database; next, exact and complete matches are used to
infer a peptide’s chromosomal coordinates; ﬁnally, the results
are loaded into the PeptideAtlas relational database. We
denote each execution of the mapping process as a ‘build’.
The database schema (available at project website http://www.
peptideatlas.org) can accommodate multiple PeptideAtlas
builds, that is, it can handle a variety of organisms and a
variety of reference protein sequence sets. Visualization of
the results is then achieved using the Distributed Annotation
System (DAS) (4) in conjunction with the Ensembl genome
browser (5).
Owing to growing interest from the scientiﬁc community,
other PeptideAtlas builds were added to the initial human
PeptideAtlas (6), including a build for human plasma/serum
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doi:10.1093/nar/gkj040(7) and for other species such as Drosophila melanogaster and
yeast Saccharomyces cerevisiae. A summary of the currently
available builds is shown in Figure 2.
FEATURES OF PeptideAtlas
The current Human build of PeptideAtlas (April 2005) con-
tains peptide sequences identiﬁed in 90 proteomic experi-
ments, in which proteins were extracted from various cell
and tissue types. This number of experiments represents a
considerable increase compared with the original build (6)
and comprises published as well as a large number of (yet)
unpublished human datasets from various cell types, such as
T cells, B cells, lymphocytes, lymphoblasts, hepatocytes,
intestinal cells, hepatoma cells and others. A full listing of
all the experiments and samples currently in PeptideAtlas can
be found at the project website. The raw data for all published
or released datasets are also provided in a repository there. In
the April 2005 build, 3.3 million MS/MS spectra were
searched and yielded 35391 distinct peptides with Peptide-
Prophet probability P > 0.9 that were mapped onto 11115 of
the human Ensembl proteins (version 30.35c; March 22,
2005). These proteins represent unique proteins or splice
forms from 30% of human genes in Ensembl.
Figure 2 also shows the cumulative number of distinctly
identiﬁed peptides as a function of the number of spectra with
PeptideProphet probability P > 0.9 identiﬁcations. When
most peptides that can be observed with the technology used
are catalogued, this curve is expected to ﬂatten—each
additional dataset should then yield few new gene matches.
However, most curves continue to increase steeply with
the exception of yeast, where ﬂattening is evident due to a
large number of similar experiments. The last yeast experi-
ment to be added showed a signiﬁcant increase in contributed
peptides as a new free-ﬂow electrophoresis fractionation
technique was used, allowing many previously unidentiﬁed
peptides to be detected.
Repository function. It is our intent to make publicly avail-
able for download as much of the raw data that we use to build
the PeptideAtlas as possible. This includes datasets that have
been previously published or otherwise released by the data
producers. Unpublished raw datasets that were used to build
PeptideAtlas are kept privateuntilpublicationorreleaseby the
authors.Therearecurrently75humanandyeastexperiments
available for download in the repository, totaling over 85 GB
of downloads. We provide for download the raw MS/MS ﬁles,
mzXML format MS/MS ﬁles (8), full SEQUEST search res-
ults, PeptideProphet results as well as the ﬁnal ProteinProphet
(9) output ﬁle. Simple sample descriptions and links to related
publications are also provided.
Database function. The results from the PeptideAtlas builds
can be downloaded or browsed by users via the PeptideAtlas
web interface, as depicted in Figure 3. The database function-
ality is provided by SBEAMS. The interface allows users to
select and browse experimentally observed peptides that
match available constraints. There is a summary page at the
peptide level, displaying attributes and mappings for a single
peptide sequence, and also a summary page at the protein
level, displaying attributes of a speciﬁed protein and which
peptides map to it. Visualization of the results is achieved
using the DAS in conjunction with the Ensembl genome brow-
ser. DAS allows sequence annotations to be added by multiple
third-party annotators and viewed on an as-needed basis in the
Ensembl genome browser.
Users can view the most current ISB Human PeptideAtlas
tracks in the Ensembl genome browser by following the
instructions on the website. Once the PeptideAtlas tracks
have been deﬁned, the peptide coordinate URLs in our web
database interfaces link to a view of the peptide inthe Ensembl
genome browser. From that genome view, one can also
link back to the PeptideAtlas database by clicking on the
peptide link.
STATISTICS FOR PeptideAtlas
Reliably estimating the false positive error rates in an auto-
mated fashion is critical: large-scale datasets generated by
Figure 1. PeptideAtlas analysis pipeline for the annotation of genomes with
high-quality peptide sequences derived from high-throughput 2D-LC-MS/MS
analysis of biological samples.
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large number of false identiﬁcations (10). PeptideAtlas uses
a program called PeptideProphet (9) to remove the majority of
false positive identiﬁcations. PeptideProphet computes a prob-
ability that an assignment of an MS/MS spectrum to a peptide
sequence is correct based on the database search scores, the
difference between the measured and theoretical peptide
masses, the expected and found number of termini for the
type of enzymatic cleavage used and a variety of other factors.
Probabilities computed by PeptideProphet have been shown to
be accurate in the entire probability range and, therefore, can
be used to ﬁlter out the probabilities that fall below a certain
threshold(2). We provide options for users to browse or down-
load versions of the PeptideAtlas built with several P
thresholds.
FUTURE DIRECTIONS
PeptideAtlas is a ﬁrst step toward the goal of fully annotating
and validating eukaryotic genomes by using experimentally
observed protein products. PeptideAtlas provides a process
and a framework to accommodate proteome information gen-
erated by high-throughput proteomics technologies and is able
to efﬁciently disseminate experimental data in the public
domain. Its signiﬁcance continues to grow as more data are
submitted from diverse experiments, using different cellular
compartments and enrichments methods. PeptideAtlas also
provides a resource for the development of new avenues of
research. The datasets will provide a rich source of data for
computational scientists to develop and test new algorithms
for proteomic analysis, gene-discovery and splice variant
prediction.
The need for public proteomics data repositories is recog-
nized (11) and we intend PeptideAtlas to continue to grow as a
public database and resource. We strongly encourage
researchers to contribute their own MS/MS data to the
PeptideAtlas project. In the near future, we will make builds
for organisms such as mouse, Arabidopsis thaliana and
Halobacterium sp. NRC-1, and continue to make subsets
such as the Human Plasma PeptideAtlas (7). Also in the near
Figure 2. Plots:cumulativenumberof MS/MSspectraversuscumulativenumberofdistinctpeptides(all spectraandpeptidescorrespond to peptideidentifications
with probabilities >0.9). The figure will show saturation when new spectra do not yield new peptide identifications. Tables: statistics for atlas builds (number of
experiments, number of spectra that yielded a peptide identification with probability P > 0.9, number of distinct peptides identified, number of proteins identified
and percentage of all genes to which the proteins map).
Nucleic Acids Research, 2006, Vol. 34, Database issue D657future we hope to provide an interface to access representative
spectra of peptides, and will provide a way to retrieve informa-
tion on peptide modiﬁcations (such as phosphorylation, etc.).
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Figure 3. Peptide view in the PeptideAtlas web-based database interface. For the specified peptide (by accession number or sequence) a summary is displayed
indicating individual attributes of the peptide, protein and genome mapping information, and the samples in which it has been observed. Different information is
available in other views. Additionally there are two-way links to the Ensemblgenome browserthat allow usersto see PeptideAtlas peptides as tracks in the genome
browser and link out for more information. Additional information is available at our website.
D658 Nucleic Acids Research, 2006, Vol. 34, Database issue